Immix Liabilities And Stockholders Equity from 2010 to 2025

IMMX Stock  USD 1.94  0.03  1.52%   
Immix Biopharma Liabilities And Stockholders Equity yearly trend continues to be fairly stable with very little volatility. Liabilities And Stockholders Equity will likely drop to about 12 M in 2025. Liabilities And Stockholders Equity is the total of all liabilities and equity in the company, which should equal Immix Biopharma's total assets according to the accounting equation. View All Fundamentals
 
Liabilities And Stockholders Equity  
First Reported
2010-12-31
Previous Quarter
22.9 M
Current Value
12 M
Quarterly Volatility
8.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Immix Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immix Biopharma's main balance sheet or income statement drivers, such as Tax Provision of 12.5 K, Net Interest Income of 414.7 K or Depreciation And Amortization of 6.6 K, as well as many indicators such as Dividend Yield of 0.0, Ptb Ratio of 6.91 or Book Value Per Share of 0.88. Immix financial statements analysis is a perfect complement when working with Immix Biopharma Valuation or Volatility modules.
  
Check out the analysis of Immix Biopharma Correlation against competitors.
For more information on how to buy Immix Stock please use our How to Invest in Immix Biopharma guide.

Latest Immix Biopharma's Liabilities And Stockholders Equity Growth Pattern

Below is the plot of the Liabilities And Stockholders Equity of Immix Biopharma over the last few years. It is the total of all liabilities and equity in the company, which should equal the company's total assets according to the accounting equation. Immix Biopharma's Liabilities And Stockholders Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immix Biopharma's overall financial position and show how it may be relating to other accounts over time.
Liabilities And Stockholders Equity10 Years Trend
Slightly volatile
   Liabilities And Stockholders Equity   
       Timeline  

Immix Liabilities And Stockholders Equity Regression Statistics

Arithmetic Mean6,118,754
Geometric Mean2,254,439
Coefficient Of Variation135.38
Mean Deviation7,167,156
Median942,944
Standard Deviation8,283,405
Sample Variance68.6T
Range22.4M
R-Value0.76
Mean Square Error30.5T
R-Squared0.58
Significance0.0006
Slope1,330,254
Total Sum of Squares1029.2T

Immix Liabilities And Stockholders Equity History

202512 M
202422.9 M
202319.9 M
202214.9 M
202118.2 M
2020539.6 K

About Immix Biopharma Financial Statements

Immix Biopharma investors use historical fundamental indicators, such as Immix Biopharma's Liabilities And Stockholders Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immix Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Liabilities And Stockholders Equity22.9 M12 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immix Stock Analysis

When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.